| Name | Title | Contact Details |
|---|
ON TARGET LABORATORIES discovers and develops fluorescent markers to target and illuminate cancer during surgery so it can be removed more completely.
Arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as PROTACs (PROteolysis TArgeting Chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets.
moksha8 Pharmaceuticals is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins.
Scorpion Therapeutics was founded to expand the reach of precision medicine to more people with cancer.